Develops immunotherapies for infectious diseases. Creates treatments for autoimmune diseases. Now — the numbers.
There is not enough trading history here to call this an established business.
If every debt were paid off today, $90.6M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $96.6M in the vault; even if every debt were paid off, $90.6M would remain.
Over the last 12 months, company executives reported 13 buys and 4 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.01. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.